According to Fortune Business Insights, the global Transcatheter Pulmonary Valve Market was valued at USD 78.68 million in 2025 and is projected to grow from USD 83.08 million in 2026 to USD 128.40 million by 2034, registering a CAGR of 5.59% during 2026–2034. Rising prevalence of congenital heart disorders, increasing adoption of minimally invasive cardiac procedures, and advancements in transcatheter valve replacement technologies are supporting market growth.

Transcatheter pulmonary valve implantation is increasingly used to manage conditions such as pulmonary stenosis and pulmonary regurgitation, particularly among patients requiring right ventricular outflow tract reconstruction. Growing adoption of catheter-based procedures is also supported by shorter hospitalization periods and reduced surgical trauma compared with traditional interventions.

Transcatheter Pulmonary Valve Market Growth Drivers

Rising Prevalence of Congenital Heart Disorders

The increasing prevalence of congenital heart diseases and structural cardiac abnormalities is a major factor supporting market expansion. Conditions such as pulmonary stenosis and pulmonary regurgitation can require repeated valve interventions during a patient's lifetime. The growing use of transcatheter pulmonary valve implantation provides healthcare providers with a minimally invasive treatment option while supporting shorter recovery periods.

Pediatric cardiology programs and adult congenital heart disease clinics are also expanding, improving access to specialized cardiac interventions. Advancements in imaging technologies, catheter delivery systems, and valve durability are further supporting physician adoption.

Transcatheter Pulmonary Valve Market Trends

Advancements in Valve and Catheter Technologies

Manufacturers are increasingly developing repositionable and self-expanding valve technologies designed to improve implantation precision. Advanced imaging guidance, 3D cardiac mapping, artificial intelligence, and digital cardiac imaging are also being integrated into structural heart programs.

Another important trend is the growing use of transcatheter pulmonary valve therapies among adults with congenital heart disease. Increasing survival among these patients is generating long-term demand for repeat pulmonary valve interventions. Hospitals are also establishing hybrid cardiac operating rooms and specialized structural heart programs to support minimally invasive procedures.

For detailed market insights, visit: https://www.fortunebusinessinsights.com/transcatheter-pulmonary-valve-market-117414

Transcatheter Pulmonary Valve Market Opportunities

Expansion of Minimally Invasive Cardiac Interventions

The growing preference for minimally invasive cardiovascular procedures is creating opportunities for valve manufacturers. Healthcare providers are increasingly adopting catheter-based interventions because they can reduce surgical trauma and hospitalization requirements.

Emerging healthcare economies are also investing in advanced cardiac care infrastructure, hybrid operating rooms, imaging technologies, and physician training programs. Innovation in biocompatible materials, repositionable valve systems, and smaller catheter delivery devices could further expand the addressable patient population.

Transcatheter Pulmonary Valve Market Segmentation

By Application

Based on application, the market is divided into pulmonary stenosis and pulmonary regurgitation. Pulmonary regurgitation accounted for approximately 54% of the market, making it the leading application segment. Increasing demand for minimally invasive valve replacement among patients with repaired congenital heart defects is supporting this segment. Pulmonary stenosis accounted for approximately 46% of the market.

By Technology

Based on technology, balloon-expandable valves accounted for approximately 58% of the market. Their controlled expansion, procedural stability, and accurate deployment make them widely used in specialized cardiac centers. Improvements in valve-frame durability and catheter flexibility are further supporting adoption.

By End-use and Raw Material

Hospitals represented approximately 63% of the market, supported by increasing procedural volumes and investment in structural heart programs. By raw material, biological tissue materials accounted for approximately 67%, supported by their biocompatibility and hemodynamic characteristics.

Transcatheter Pulmonary Valve Market Regional Analysis

North America

North America dominated the global market with a 44% share in 2025. Advanced cardiac care infrastructure, adoption of minimally invasive procedures, and established congenital heart disease programs are supporting regional growth. The U.S. is an important contributor, with specialized hospitals and pediatric cardiology centers increasingly performing transcatheter pulmonary valve procedures.

Europe

Europe accounted for 28% of the global market. Germany represented approximately 29% of the European market, while the U.K. accounted for around 24%. Strong healthcare infrastructure and growing adoption of structural heart interventions are supporting regional demand.

Asia-Pacific

Asia-Pacific represented approximately 21% of the global market. Japan accounted for 26% of the Asia-Pacific market, while China represented approximately 38%. Improving healthcare infrastructure, rising diagnosis of congenital heart conditions, and increasing investments in advanced cardiovascular technologies are creating opportunities across the region.

List of Top Transcatheter Pulmonary Valve Companies

Key companies operating in the market include Boston Scientific Corporation, Braile Biomedica, Artivion, Inc., Edwards Lifesciences Corporation, JenaValve Technology, Inc., LivaNova PLC, Medtronic, Venus Medtech, Lepu Medical Technology, and Jude Medical Inc. Medtronic accounted for approximately 32% of the market, while Edwards Lifesciences Corporation held around 24%.

Transcatheter Pulmonary Valve Market Challenges

High procedure costs, limited accessibility to specialized cardiac centers, and the need for highly trained interventional cardiologists can restrict adoption. Regulatory approval requirements and lengthy clinical validation processes may also increase product development timelines and costs. In addition, complex implantation procedures and concerns regarding long-term valve durability remain important considerations for healthcare providers.

Request Sample Report

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/transcatheter-pulmonary-valve-market-117414

Future Outlook

The global Transcatheter Pulmonary Valve Market is expected to expand as minimally invasive cardiac procedures gain wider adoption and manufacturers introduce more precise, durable, and flexible valve systems. Continued development of repositionable valves, biocompatible materials, AI-assisted imaging, and advanced catheter delivery systems is expected to create further opportunities. The market is projected to reach USD 128.40 million by 2034, growing at a 5.59% CAGR during 2026–2034.

What’s Driving the Global Market? Discover the Latest Transcatheter Pulmonary Valve Market Insights